Innovent Biologics Stock Return On Equity
| IVBXF Stock | USD 4.85 0.24 4.72% |
Innovent Biologics fundamentals help investors to digest information that contributes to Innovent Biologics' financial success or failures. It also enables traders to predict the movement of Innovent Pink Sheet. The fundamental analysis module provides a way to measure Innovent Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Innovent Biologics pink sheet.
Innovent |
Innovent Biologics Company Return On Equity Analysis
Innovent Biologics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Innovent Biologics Return On Equity | -0.29 |
Most of Innovent Biologics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innovent Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Innovent Biologics has a Return On Equity of -0.287. This is 98.8% lower than that of the Healthcare sector and 99.21% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 7.42% lower than that of the firm.
Innovent Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innovent Biologics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Innovent Biologics could also be used in its relative valuation, which is a method of valuing Innovent Biologics by comparing valuation metrics of similar companies.Innovent Biologics is currently under evaluation in return on equity category among its peers.
Innovent Fundamentals
| Return On Equity | -0.29 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.68) % | |||
| Operating Margin | (0.78) % | |||
| Current Valuation | 5.13 B | |||
| Shares Outstanding | 1.53 B | |||
| Shares Owned By Insiders | 7.15 % | |||
| Shares Owned By Institutions | 44.34 % | |||
| Price To Book | 4.22 X | |||
| Price To Sales | 1.39 X | |||
| Revenue | 4.27 B | |||
| Gross Profit | 2.98 B | |||
| EBITDA | (2.99 B) | |||
| Net Income | (3.14 B) | |||
| Cash And Equivalents | 8.32 B | |||
| Cash Per Share | 5.67 X | |||
| Total Debt | 2.02 B | |||
| Debt To Equity | 0.29 % | |||
| Current Ratio | 3.21 X | |||
| Book Value Per Share | 6.54 X | |||
| Cash Flow From Operations | (2.02 B) | |||
| Earnings Per Share | (0.32) X | |||
| Number Of Employees | 5.54 K | |||
| Beta | 0.16 | |||
| Market Capitalization | 8.37 B | |||
| Total Asset | 16.24 B | |||
| Z Score | 2.4 | |||
| Net Asset | 16.24 B |
About Innovent Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innovent Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innovent Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innovent Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Innovent Pink Sheet
Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.